


GLPG3970

Cat. No.:	HY-150203		
CAS No.:	2403733-82-2		
Molecular Formula:	C ₂₅ H ₂₇ F ₃ N ₄ O ₄		
Molecular Weight:	504.5		
Target:	Salt-inducible Kinase (SIK)		
Pathway:	Immunology/Inflammation		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (198.22 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
	Preparing Stock Solutions		10 mg	
	1 mM	1.9822 mL	9.9108 mL	19.8216 mL
	5 mM	0.3964 mL	1.9822 mL	3.9643 mL
	10 mM	0.1982 mL	0.9911 mL	1.9822 mL
Please refer to the solubility information to select the appropriate solvent.				
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (4.96 mM); Clear solution; Need ultrasonic			
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (4.96 mM); Clear solution; Need ultrasonic			
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 2.5 mg/mL (4.96 mM); Clear solution; Need ultrasonic			

BIOLOGICAL ACTIVITY

Description	GLPG3970 (compound 88) is a first-in-class SIK2/SIK3 inhibitor. GLPG3970 can be used for the research of inflammation and autoimmune disease ^[1] .
In Vivo	GLPG3970 (10 mg/kg; oral administration; twice daily for 5 consecutive days) decreases the ear thickness of murine models of psoriatic-like epidermal hyperplasia induced by intradermal injections of IL-23 ^[1] . GLPG3970 (60 mg/kg; oral administration; twice daily until mice are sacrificed) shows better clinical manifestations compared to vehicle groups in murine collagen-antibody induced arthritis model (CAIA) ^[1] .

GLPG3970 (30 mg/kg; oral administration; twice daily for 7 consecutive days) reduces disease activity index compared to vehicle groups in mice T cell transfer model^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. DESROY N, et al. NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES. WO/2019/238424. 2019.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA